Absolutely. Maybe I'll come back to my earlier comment that with all of these initiatives, the devil is in the details.
I mentioned the example of the pneumococcal conjugate vaccine in the previous AMC. Just to give you a sense of what that looks like, in that instance the vaccine was available. The lowest local price was $3.10 per dose. You need three doses to confer immunity. Because humanitarians did not have a specific humanitarian mechanism to access it when we wanted to access it to vaccinate 5,000 refugee children in Greece, we were charged a price of $68.10 per dose. That's your gap.
The funding of COVAX is absolutely essential. This is the international mechanism we're looking at for procuring vaccines for low- and middle-income countries. I think we need to have a conversation around how humanitarian organizations are going to access it. It's a bit difficult to plan down the road because we don't actually know what vaccines we're talking about specifically. That introduces questions of cold chain vaccination strategies and those sorts of things. Again, there's a big conversation to be had once we know more specifically what we're talking about.
I think it's really important that Canada not only be a donor to COVAX, but contribute—and continue to contribute, because there certainly is a lot of energy going into this—to make sure that this is being designed and implemented to be guided by principles of equitable and affordable access.
Again, this comes back to the issues of transparency. Let's be transparent about what the not-for-profit price is that's being put forward. Let's make sure that we're getting a good deal and that doses are being sourced and procured as quickly and as affordably as possible.